60 related articles for article (PubMed ID: 19563826)
21. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
22. Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones.
Kensler TW; Egner PA; Dolan PM; Groopman JD; Roebuck BD
Cancer Res; 1987 Aug; 47(16):4271-7. PubMed ID: 2886217
[TBL] [Abstract][Full Text] [Related]
23. Oxidized metabolites of oltipraz exert cytoprotective effects against arachidonic acid through AMP-activated protein kinase-dependent cellular antioxidant effect and mitochondrial protection.
Kwon YN; Shin SM; Cho IJ; Kim SG
Drug Metab Dispos; 2009 Jun; 37(6):1187-97. PubMed ID: 19299524
[TBL] [Abstract][Full Text] [Related]
24. Repression of protein synthesis and mTOR signaling in rat liver mediated by the AMPK activator aminoimidazole carboxamide ribonucleoside.
Reiter AK; Bolster DR; Crozier SJ; Kimball SR; Jefferson LS
Am J Physiol Endocrinol Metab; 2005 May; 288(5):E980-8. PubMed ID: 15613684
[TBL] [Abstract][Full Text] [Related]
25. Cellular kinetics of induction by oltipraz and its keto derivative of detoxication enzymes in human colon adenocarcinoma cells.
O'Dwyer PJ; Clayton M; Halbherr T; Myers CB; Yao Ks
Clin Cancer Res; 1997 May; 3(5):783-91. PubMed ID: 9815750
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of chemoprotection by oltipraz.
Kensler T; Styczynski P; Groopman J; Helzlsouer K; Curphey T; Maxuitenko Y; Roebuck BD
J Cell Biochem Suppl; 1992; 16I():167-72. PubMed ID: 1305682
[TBL] [Abstract][Full Text] [Related]
27. Dithiolethiones for cancer chemoprevention: where do we stand?
Zhang Y; Munday R
Mol Cancer Ther; 2008 Nov; 7(11):3470-9. PubMed ID: 19001432
[TBL] [Abstract][Full Text] [Related]
28. Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies.
Lee YA; Friedman SL
J Intern Med; 2022 Jan; 291(1):11-31. PubMed ID: 34564899
[TBL] [Abstract][Full Text] [Related]
29. Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming.
Jeong SW
Diabetes Metab J; 2020 Oct; 44(5):640-657. PubMed ID: 33115209
[TBL] [Abstract][Full Text] [Related]
30. Adipokines in Liver Cirrhosis.
Buechler C; Haberl EM; Rein-Fischboeck L; Aslanidis C
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28661458
[TBL] [Abstract][Full Text] [Related]
31. Posttranslational Modifications of Lipid-Activated Nuclear Receptors: Focus on Metabolism.
Becares N; Gage MC; Pineda-Torra I
Endocrinology; 2017 Feb; 158(2):213-225. PubMed ID: 27925773
[TBL] [Abstract][Full Text] [Related]
32. Targeting Hepatic Fibrosis in Autoimmune Hepatitis.
Montano-Loza AJ; Thandassery RB; Czaja AJ
Dig Dis Sci; 2016 Nov; 61(11):3118-3139. PubMed ID: 27435327
[TBL] [Abstract][Full Text] [Related]
33. Nature and Implications of Oxidative and Nitrosative Stresses in Autoimmune Hepatitis.
Czaja AJ
Dig Dis Sci; 2016 Oct; 61(10):2784-2803. PubMed ID: 27411555
[TBL] [Abstract][Full Text] [Related]
34. Dietary walnut reduces hepatic triglyceride content in high-fat-fed mice via modulation of hepatic fatty acid metabolism and adipose tissue inflammation.
Choi Y; Abdelmegeed MA; Akbar M; Song BJ
J Nutr Biochem; 2016 Apr; 30():116-25. PubMed ID: 27012628
[TBL] [Abstract][Full Text] [Related]
35. AhR expression is increased in hepatocellular carcinoma.
Liu Z; Wu X; Zhang F; Han L; Bao G; He X; Xu Z
J Mol Histol; 2013 Aug; 44(4):455-61. PubMed ID: 23547017
[TBL] [Abstract][Full Text] [Related]
36. Induction of human fetal hemoglobin via the NRF2 antioxidant response signaling pathway.
Macari ER; Lowrey CH
Blood; 2011 Jun; 117(22):5987-97. PubMed ID: 21464371
[TBL] [Abstract][Full Text] [Related]
37. Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice.
Yu Z; Shao W; Chiang Y; Foltz W; Zhang Z; Ling W; Fantus IG; Jin T
Diabetologia; 2011 Apr; 54(4):922-34. PubMed ID: 21161163
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic potential of dithiolethiones for hepatic diseases.
Brooks SC; Brooks JS; Lee WH; Lee MG; Kim SG
Pharmacol Ther; 2009 Oct; 124(1):31-43. PubMed ID: 19563826
[TBL] [Abstract][Full Text] [Related]
39. Identification of a novel class of dithiolethiones that prevent hepatic insulin resistance via the adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway.
Bae EJ; Yang YM; Kim JW; Kim SG
Hepatology; 2007 Sep; 46(3):730-9. PubMed ID: 17668885
[TBL] [Abstract][Full Text] [Related]
40. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones.
Hwahng SH; Ki SH; Bae EJ; Kim HE; Kim SG
Hepatology; 2009 Jun; 49(6):1913-25. PubMed ID: 19378344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
